To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 04, 2020___

Today's Rundown

Featured Story

AstraZeneca's HQ budget balloons to 3 times original forecast

The forecast cost of AstraZeneca’s new headquarters in Cambridge, U.K., has ballooned to $1.3 billion (£1 billion), more than three times the original target. AstraZeneca blamed the overspend on the complexity of the build, construction cost inflation and other factors.

Top Stories

Alnylam, Vir team up to develop siRNAs to tackle COVID-19

Alnylam and Vir Biotechnology have teamed up to develop RNAi therapeutics against the coronavirus behind the COVID-19 outbreak. The collaboration builds on Alnylam synthesis of siRNAs that target highly conserved regions of coronavirus RNA.

Financial volatility be damned: ORIC guns for $86M IPO

After a $55 million series D last year, ORIC Pharma is taking the next inevitable step: an IPO, as it looks to trial drug-resistant cancers.

Akouos nabs meaty $105M raise, adds VC and biotech veterans to board

Boston-based hearing loss gene therapy biotech Akouos has grabbed a $105 million series B funding round.

Amunix raises $73M to take T-cell engager into humans

Amunix Pharmaceuticals has raised $73 million in series A funding. The Omega Funds-led round sets Amunix up to move its lead T-cell engager into the clinic after years of licensing its half-life extension technology to leading drug developers for their own candidates. 

Thermo Fisher finally lands Qiagen with $11.5B deal

After months of a public back-and-forth over a potential acquisition, Thermo Fisher Scientific President and CEO Marc Casper said he and Qiagen’s leadership finally had a “meeting of the minds” on how to move forward—and $11.5 billlion later, they’ve set a target date for the first half of 2021.

China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend Roche's blockbuster arthritis drug Actemra to tackle that rampage.

Enrollment Showcase

What's the value of an MBA to healthcare and the life sciences?

Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. 

Resources

[Whitepaper] Create A More Compelling Program Development Dossier With Metabolomics

Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe.

[eBook] 9 Ways to Enhance Healthcare Customer Experiences

Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing.

[Whitepaper] The ROI of Document Delivery

3 ways you may be overspending on scientific literature access, and how to fix them.

[Whitepaper] Manufacturing Cytotoxic and Non-Cytotoxic

When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed.  Outsourcing to a CMO with experience in multiproduct facilities can be an option.

[Whitepaper] Measure the Right Things at the Right Time: Using A Metric Maturity Model to Optimize Performance Measurement

Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way.

[Whitepaper] Strategies for Improving Software Deployments and Business Processes Adoption Rates

Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change.

[Whitepaper] Navigating Today’s Healthcare Transformation: The Evolution of Payers

Read about the innovative ways payers are making smart moves in the healthcare game.

[Video] FierceBiotech Sits Down With H1

Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1.

[Whitepaper] Successful BYOD in Any Phase

Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial.

[Executive Summary] Strategies for Flexible Manufacturing

This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market.

[Video] FierceBiotech Sits Down With Accenture

Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. 

[Whitepaper] Achieving Differentiation in the Complex Oncology Market

White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done.

[Presentation] Flexible Manufacturing Strategies

Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible.

[Executive Summary] Overcoming Manufacturing Challenges for Accelerated Drug Development

Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project.

[Executive Summary] Clinical Supplies - Made to Order

Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

[Whitepaper] Digital Twins: Creating Digital Operations Today to Deliver Business Value Tomorrow

This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future.

[Q&A] Embarking Upon the Commercial Manufacturing Journey for a Biologic

In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey.

Events